Roche identifies blood glucose measurement with the Cobas Pulse System
There is a new blood glucose monitor hitting the market in Europe, and its producer, Big Pharma titan Roche, is working to bring it to market in the US and other regions as soon as possible. The cobas pulse system was designed to streamline blood collection and testing processes for hospital professionals, and the point-of-care monitor is paired with a smartphone-like companion device that can run its own apps.
Features include a touchscreen and camera for additional diagnostic needs, an automated glucose test strip reader, and an easy-to-hold rugged case that makes deep disinfection easy. Additionally, it is intended for use in patients of all ages and types, which means intensive care patients as well as neonates can benefit from the cobas pulse.
Speaking about the heavy burden currently placed on the industry’s workforce, Roche Diagnostics CEO Thomas Schinecker said: “Frontline healthcare workers are under increasing pressure not only to diagnose with patients, but also to make appropriate decisions about all aspects of disease management and patient care.
Cloud technology provider Glytec was asked to leverage its Glucommander insulin dosing program to provide cobas pulse software. Running the Glucommander assay software directly on the blood glucose meters themselves will greatly save clinicians time and improve quality of care. cobas pulse is also compatible with other downloadable decision support applications such as CardioSignal, SteadSense and Smart4Diagnostics.